82 completed, 17 terminated, 16 recruiting, 10 active not recruiting. 61 Phase 3, 40 Phase 1, 29 Phase 2, 2 Phase 4, 1 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 3 | 61 | Completed 36, Recruiting 8, Terminated 7, Active not recruiting 6, Enrolling by invitation 3, Withdrawn 1 |
| Phase 1 | 40 | Completed 28, Terminated 5, Recruiting 4, Active not recruiting 2, Withdrawn 1 |
| Phase 2 | 29 | Completed 18, Terminated 6, Recruiting 4, Active not recruiting 1 |
| Phase 4 | 2 | Active not recruiting 1, Completed 1 |
| Not applicable | 1 | Completed 1 |
Follow UCB Biopharma SRL: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab - Ocular Myasthenia Gravis | Phase 3 | Recruiting | 100 | 2026-09-16 | 2026-10-27 |
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis
Galvokimig, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | 300 | 2026-08-05 | 2026-10-27 |
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
Galvokimig, Placebo - Chronic Obstructive Pulmonary Disease With Chronic Bronchitis | Phase 2 | Recruiting | 402 | 2026-07-27 | 2026-10-27 |
SLC6A1-NDD Prospective Longitudinal Natural History Study
SLC6A1 Neurodevelopmental Disorder (NDD), Developmental and Epileptic Encephalopathies (DEE) | | Recruiting | 60 | 2026-07-21 | 2026-07-31 |
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab, Placebo - Ocular Myasthenia Gravis | Phase 3 | Recruiting | 120 | 2026-05-27 | 2026-10-27 |
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
Galvokimig, Placebo - Atopic Dermatitis | Phase 2 | Active not recruiting | 165 | 2025-12-29 | 2026-09-25 |
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc - Psoriatic Arthritis, Axial Spondyloarthritis | Phase 1 | Recruiting | 392 | 2025-12-10 | 2026-07-06 |
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants
UCB5285, Placebo - Healthy Participants | Phase 1 | Active not recruiting | 80 | 2025-12-08 | 2026-07-24 |
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Rozanolixizumab - Myasthenia Gravis | Phase 4 | Active not recruiting | 40 | 2025-12-01 | 2026-10-29 |
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
Bimekizumab, Placebo - Palmoplantar Pustulosis | Phase 3 | Recruiting | 320 | 2025-11-14 | 2026-08-27 |
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
Bimekizumab - Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis | Phase 1 | Recruiting | 20 | 2025-11-05 | 2026-09-18 |
A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants
UCB0022 - Healthy Volunteers | Phase 1 | Completed | 14 | 2025-10-23 | 2026-01-06 |
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Zilucoplan - Healthy Participants | Phase 1 | Recruiting | 15 | 2025-07-09 | 2026-08-27 |
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Staccato Alprazolam, Midazolam, Diazepam - Healthy Participants | Phase 1 | Completed | 55 | 2025-06-12 | 2026-02-20 |
A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese Participants
glovadalen, Placebo - Healthy Study Participants | Phase 1 | Completed | 32 | 2025-04-28 | 2026-06-22 |
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Bimekizumab - Hidradenitis Suppurativa | Phase 3 | Active not recruiting | 43 | 2025-04-07 | 2026-09-25 |
An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Bimekizumab - Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis | Phase 3 | Recruiting | 40 | 2025-03-11 | 2026-10-23 |
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
Donzakimig, Placebo - Healthy Participants | Phase 1 | Completed | 32 | 2024-12-06 | 2026-02-18 |
A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
Rozanolixizumab - Healthy Participants | Phase 1 | Completed | 15 | 2024-12-03 | 2026-06-04 |
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
DZP, Placebo - Systemic Lupus Erythematosus | Phase 3 | Recruiting | 450 | 2024-11-21 | 2026-10-15 |
Showing 20 of 134. Sign in to see all of them.
Conditions studied
Myasthenia Gravis (15) · Epilepsy (14) · Psoriasis (13) · Arthritis, Psoriatic (12) · Axial Spondyloarthritis (7) · Hidradenitis Suppurativa (6) · Parkinson Disease (6) · Dermatitis, Atopic (4) · Spondylitis, Ankylosing (4) · Arthritis, Rheumatoid (3) · Crohn Disease (3) · Epilepsy, Absence (3) · Lupus Erythematosus, Systemic (3) · Purpura, Thrombocytopenic, Idiopathic (3) · Arthritis (2)
Interventions
bimekizumab (35) · rozanolixizumab (20) · brivaracetam (11) · Certolizumab Pegol (8) · zilucoplan (7) · Adalimumab (4) · Alprazolam (4) · Lacosamide (3) · dapirolizumab pegol (3) · padsevonil (3) · Ustekinumab (2) · rotigotine (2) · Biopsy (1) · Data Collection (1) · Diazepam (1)
Countries
United States (89) · Germany (64) · Poland (56) · United Kingdom (54) · Spain (48) · Italy (40) · Canada (39) · Japan (37) · France (36) · Czechia (34) · Hungary (33) · Belgium (31) · Australia (26) · Bulgaria (22) · China (20)
Top investigators
Daniela Berg, Prof.Dr. (1) · Fiona Thistlethwaite, Prof (1)
Results publications
PMID 40194794, PMID 41807031, PMID 35544084, PMID 42386286, PMID 39578348, PMID 41060492, PMID 41580158, PMID 41800601, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 37059507, PMID 38446397, PMID 38488975, PMID 38754125, PMID 39120849, PMID 39215949, PMID 39534481, PMID 40347389, PMID 41125403, PMID 41248770, PMID 41314667, PMID 41381988, PMID 41838419, PMID 42128532, PMID 42152504, PMID 42297437, PMID 42388397, PMID 42482599, PMID 42525209, PMID 42860055, PMID 34260044, PMID 36649967, PMID 36689515, PMID 37793792, PMID 38073049, PMID 38588819, PMID 38599650, PMID 38795716, PMID 38834351, PMID 38977276, PMID 39120848, PMID 39133438, PMID 39313302, PMID 39406403, PMID 39892885, PMID 40105996, PMID 40153232
NIH funding
2019 (17), 2023 (16), 2017 (12), 2016 (8), 2018 (4), 2025 (4), 2015 (2)